All In Biotech

Drug Trial Radar · NCT06134362

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

A Phase IIIB, Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,998

Actual

Start

May 14, 2024

Primary completion

Mar 14, 2029

Study completion Mar 14, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline; PPD Development, LP
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal.

Conditions

  • HIV Infections

Interventions

  • CAB LADrug

    Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with new HIV infectionTime frame: From Day 1 up to end of study (up to approximately [approx.] 3 years)
  2. Number of participants with new HIV infection by characteristicTime frame: From Day 1 up to end of study (up to approx. 3 years)

Locations

33 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Almagro, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Francistown, Botswana

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Mbabane, Eswatini

  • GSK Investigational Site

    Kisumu, Kenya

  • GSK Investigational Site

    Blantyre, Malawi

  • GSK Investigational Site

    Lilongwe, Malawi

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Lima, Peru

  • GSK Investigational Site

    Piura, Peru

  • GSK Investigational Site

    Cape Town, South Africa

  • GSK Investigational Site

    City of Cape Town, South Africa

  • GSK Investigational Site

    City of Cape Town, South Africa

  • GSK Investigational Site

    City of Johannesburg, South Africa

  • GSK Investigational Site

    Durban, South Africa

  • GSK Investigational Site

    Durban, South Africa

  • GSK Investigational Site

    Isipingo, South Africa

  • GSK Investigational Site

    Sol Plaatjie, South Africa

  • GSK Investigational Site

    Pathum Wan, Thailand

  • GSK Investigational Site

    Chiang Mai, Chiang Mai, Thailand

  • GSK Investigational Site

    Entebbe, Uganda

  • GSK Investigational Site

    Kampala, Uganda

  • GSK Investigational Site

    Hanoi, Vietnam

  • GSK Investigational Site

    Chitungwiza, Zimbabwe

  • GSK Investigational Site

    Chitungwiza, Zimbabwe

  • GSK Investigational Site

    Chitungwiza, Zimbabwe

  • GSK Investigational Site

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.